DIVI S LABORATORIES LTD

Manufactures active pharmaceutical ingredients (APIs) and intermediates, splitting revenue roughly 45% from generic APIs and 55% from custom synthesis (CS) for innovator drug companies. Exports account for 89% of sales across 80 countries, with Europe and the US together at 74% of revenue. Operates manufacturing units including Unit 3 at Kakinada, where a ₹1,500 crore expansion is underway with ₹600 crores already capitalized and CWIP standing at ₹2,113 crores as of March 31, 2026. Is scaling peptide manufacturing with several 3,000-litre SPPS reactors validated across multiple therapeutic categories, targeting global top-2 peptide scale. Has iodine-based contrast media in commercial stage and Gadolinium in Phase II/III qualification, alongside three dedicated CS projects awaiting customer regulatory approvals for commercialization. Raw materials are the largest input cost at 41.5% of revenue, with roughly 40% of raw materials imported, providing a natural hedge against export earnings. FY26 consolidated revenue was ₹10,560 crores and PAT ₹2,568 crores; Q1 FY27 total income reached ₹3,144 crores with PAT of ₹902 crores.